Biopharmaceutical News and Research

RSS
New Associate Director of Business Development appointed by ERT

New Associate Director of Business Development appointed by ERT

Lakewood-Amedex to speed up development of its broad spectrum anti-influenza product into clinical studies

Lakewood-Amedex to speed up development of its broad spectrum anti-influenza product into clinical studies

Novelos Therapeutics enters into a definitive agreement with Purdue Pharma to raise funds

Novelos Therapeutics enters into a definitive agreement with Purdue Pharma to raise funds

Morria Biopharmaceuticals receives approval to commence its Phase II clinical trial on MRX6

Morria Biopharmaceuticals receives approval to commence its Phase II clinical trial on MRX6

Tikcro Technologies announces financial results for the second-quarter ended June 30, 2009

Tikcro Technologies announces financial results for the second-quarter ended June 30, 2009

Profectus BioSciences to conduct proof-of-concept studies with its rVSV vector technology

Profectus BioSciences to conduct proof-of-concept studies with its rVSV vector technology

DATATRAK International signs two new studies with a global research-based biopharmaceutical company

DATATRAK International signs two new studies with a global research-based biopharmaceutical company

Shire collaborates with Santaris Pharma to develop Locked Nucleic Acid technology

Shire collaborates with Santaris Pharma to develop Locked Nucleic Acid technology

Cytrx’s study offers a better perception of arimoclomol's mechanism of action in induced animal stroke

Cytrx’s study offers a better perception of arimoclomol's mechanism of action in induced animal stroke

Bioniche Life Sciences update on Phase III clinical program for evaluating Urocidin

Bioniche Life Sciences update on Phase III clinical program for evaluating Urocidin

Santaris Pharma to discover and develop new RNA-based medicines for treating rare genetic disorders

Santaris Pharma to discover and develop new RNA-based medicines for treating rare genetic disorders

Profibrix raises funds for clinical and preclinical development

Profibrix raises funds for clinical and preclinical development

John R. Walsh to be responsible for continued expansion of IMS' payer and government solution initiatives

John R. Walsh to be responsible for continued expansion of IMS' payer and government solution initiatives

Orient Pharma granted commercialization rights for a drug candidate by DURECT

Orient Pharma granted commercialization rights for a drug candidate by DURECT

Synco Bio to manufacture Versartis type 2 diabetes drug candidate

Synco Bio to manufacture Versartis type 2 diabetes drug candidate

Biospecifics Technologies reports Q2 2009 financials

Biospecifics Technologies reports Q2 2009 financials

Forest Labs and Astrazeneca to co-develop and commercialize ceftaroline

Forest Labs and Astrazeneca to co-develop and commercialize ceftaroline

Inhibitex reports Q2 2009 financials

Inhibitex reports Q2 2009 financials

VIVUS reports Q2 2009 financials

VIVUS reports Q2 2009 financials

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.